Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma

Secretory clusterin (sCLU) is expressed in numerous cancers and is associated with the resistance to chemotherapy. However, the role of sCLU in the resistance of hepatocellular carcinoma (HCC) to oxaliplatin (OXA), a recently used third‐generation platinum agent, remains unclear. The stable transfec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Xiu, Peng, Dong, Xuesong, Dong, Xiaofeng, Xu, Zongzhen, Zhu, Huaqiang, Liu, Feng, Wei, Zheng, Zhai, Bo, Kanwar, Jagat R., Jiang, Hongchi, Li, Jie, Sun, Xueying
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2013
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657244/
https://ncbi.nlm.nih.gov/pubmed/23279642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12088
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars